Eli Lilly (LLY), Incyte (INCY) Achieve Primary Endpoint in Baricitinib Phase IIb as JAK Inhibitor
Go back to Eli Lilly (LLY), Incyte (INCY) Achieve Primary Endpoint in Baricitinib Phase IIb as JAK Inhibitor| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 127.22 -1.25 (0.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.47 | 52 Week High | $118.49 | |||
| Open | $127.10 | 52 Week Low | $55.00 | |||
| Day High | $129.80 | P/E | N/A | |||
| Day Low | $126.71 | EPS | $-0.56 | |||
| Volume | 1,207,137 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1244.40 -35.94 (2.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1280.34 | 52 Week High | $88.16 | |||
| Open | $1274.13 | 52 Week Low | $67.88 | |||
| Day High | $1280.28 | P/E | 288.06 | |||
| Day Low | $1243.23 | EPS | $4.32 | |||
| Volume | 2,621,172 | |||||
